Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kinnate Biopharma Inc (NQ: KNTE )

6.760 +0.650 (+10.64%)
Streaming Delayed Price Updated: 10:51 AM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kinnate Biopharma Inc

< Previous 1 2 Next >
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
From Kinnate Biopharma
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
From Kinnate Biopharma
Via Globe NewsWire
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67... 
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Walmart To Surge Around 9%? Plus B of A Securities Slashes PT On This Stock By 80%
Credit Suisse raised the price target on Walmart Inc. (NYSE: WMT) from $145 to $160. Credit Suisse analyst Robert Moskow maintained an Outperform rating on the stock. Walmart shares fell 0.5% to... 
Via Benzinga
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via Globe NewsWire
Cameco, Kinnate Biopharma And Other Big Losers From Wednesday
U.S. stocks closed slightly lower on Wednesday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Silver Drops Sharply; Owens & Minor Shares Slide
U.S. stocks traded mostly higher toward the end of trading, following the release of PPI data for September. 
Via Benzinga
Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday
Gainers Pintec Technology Holdings Limited (NASDAQ: PT) shares jumped 216.2% to close at $0.9058 on Wednesday. 
Via Benzinga
Why T2 Biosystems Shares Are Trading Lower By Over 28%, Here Are 41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Code Chain New Continent Limited (NYSE: CCNC) shares jumped 74% to $0.2868 after declining around 14% on Tuesday. 
Via Benzinga
Nasdaq Edges Lower; Crude Oil Down 2%
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
Via Benzinga
Dow Gains Over 50 Points; US Producer Prices Rise 0.4% In September
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Wednesday. 
Via Benzinga
Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
From Kinnate Biopharma
Via Globe NewsWire
33 Stocks Moving In Friday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
  
Via Benzinga
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
Bristol Myers is moving deeper into the targeted oncology space. 
Via Investor's Business Daily
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.